In vitro effect of a non-immunosuppressive FKBP ligand, FK1706, on SARS-CoV-2 replication in combination with antivirals

FKBP, a naturally occurring ubiquitous intracellular protein, has been proposed as a potential target for coronavirus replication. A non-immunosuppressive FKBP ligand, FK1706, was studied in vitro in a Vero cell model to assess potential activity alone and in combination with antivirals against SARS...

Descripción completa

Detalles Bibliográficos
Autores principales: Fitzsimmons, William E., Hartman, Tracy L., Mendenhall, Michelle, Chen, Catherine Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845424/
https://www.ncbi.nlm.nih.gov/pubmed/35169800
http://dx.doi.org/10.1101/2022.02.03.479080
_version_ 1784651673377964032
author Fitzsimmons, William E.
Hartman, Tracy L.
Mendenhall, Michelle
Chen, Catherine Z.
author_facet Fitzsimmons, William E.
Hartman, Tracy L.
Mendenhall, Michelle
Chen, Catherine Z.
author_sort Fitzsimmons, William E.
collection PubMed
description FKBP, a naturally occurring ubiquitous intracellular protein, has been proposed as a potential target for coronavirus replication. A non-immunosuppressive FKBP ligand, FK1706, was studied in vitro in a Vero cell model to assess potential activity alone and in combination with antivirals against SARS-CoV-2 replication. When combined with remdesivir, synergistic activity was seen (summary synergy score 24.7±9.56). FK1706 warrants in vivo testing as a potential new combination therapeutic for the treatment of COVID-19 infections.
format Online
Article
Text
id pubmed-8845424
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-88454242022-02-16 In vitro effect of a non-immunosuppressive FKBP ligand, FK1706, on SARS-CoV-2 replication in combination with antivirals Fitzsimmons, William E. Hartman, Tracy L. Mendenhall, Michelle Chen, Catherine Z. bioRxiv Article FKBP, a naturally occurring ubiquitous intracellular protein, has been proposed as a potential target for coronavirus replication. A non-immunosuppressive FKBP ligand, FK1706, was studied in vitro in a Vero cell model to assess potential activity alone and in combination with antivirals against SARS-CoV-2 replication. When combined with remdesivir, synergistic activity was seen (summary synergy score 24.7±9.56). FK1706 warrants in vivo testing as a potential new combination therapeutic for the treatment of COVID-19 infections. Cold Spring Harbor Laboratory 2022-02-07 /pmc/articles/PMC8845424/ /pubmed/35169800 http://dx.doi.org/10.1101/2022.02.03.479080 Text en https://creativecommons.org/licenses/by-nd/4.0/This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, and only so long as attribution is given to the creator. The license allows for commercial use.
spellingShingle Article
Fitzsimmons, William E.
Hartman, Tracy L.
Mendenhall, Michelle
Chen, Catherine Z.
In vitro effect of a non-immunosuppressive FKBP ligand, FK1706, on SARS-CoV-2 replication in combination with antivirals
title In vitro effect of a non-immunosuppressive FKBP ligand, FK1706, on SARS-CoV-2 replication in combination with antivirals
title_full In vitro effect of a non-immunosuppressive FKBP ligand, FK1706, on SARS-CoV-2 replication in combination with antivirals
title_fullStr In vitro effect of a non-immunosuppressive FKBP ligand, FK1706, on SARS-CoV-2 replication in combination with antivirals
title_full_unstemmed In vitro effect of a non-immunosuppressive FKBP ligand, FK1706, on SARS-CoV-2 replication in combination with antivirals
title_short In vitro effect of a non-immunosuppressive FKBP ligand, FK1706, on SARS-CoV-2 replication in combination with antivirals
title_sort in vitro effect of a non-immunosuppressive fkbp ligand, fk1706, on sars-cov-2 replication in combination with antivirals
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845424/
https://www.ncbi.nlm.nih.gov/pubmed/35169800
http://dx.doi.org/10.1101/2022.02.03.479080
work_keys_str_mv AT fitzsimmonswilliame invitroeffectofanonimmunosuppressivefkbpligandfk1706onsarscov2replicationincombinationwithantivirals
AT hartmantracyl invitroeffectofanonimmunosuppressivefkbpligandfk1706onsarscov2replicationincombinationwithantivirals
AT mendenhallmichelle invitroeffectofanonimmunosuppressivefkbpligandfk1706onsarscov2replicationincombinationwithantivirals
AT chencatherinez invitroeffectofanonimmunosuppressivefkbpligandfk1706onsarscov2replicationincombinationwithantivirals

Ejemplares similares